NAVIRFA, a new 3D image-guided medical system NaviFUS has been developing, was recently showcased at the 1st International Asia-Pacific Advancements in Medical Ultrasound Forum. Currently in the verification and testing stage, NAVIRFA can help solve “unmet needs” of current RFA surgery practices through innovative 3D imaging and other diagnostic improvements in accuracy and speed. It is expected to obtain US and Taiwan marketing authorization next year. NAVIRFA will primarily be applied to liver cancer patients, which comprise a rapidly growing population of cancer patients. Liver cancer is the sixth most common cancer in the world, with Taiwan and Asia as the most prevalent regions. The new technology behind NAVIRFA is primed to helping alleviate the liver disease burden in Asia Pacific and meeting escalating market demand…
NaviFUS qualified for entry into the 2019 Taipei Biotech Awards and will present at the prize-winners’ pavilion during the event at Nangang Exhibition Hall. NaviFUS also announced that the safety study for “Focused Ultrasound-induced Blood Brain Barrier (BBB) Disruption in recurrent Glioblastoma patients” has been completed in June, with the case report to be completed in August. The study was conducted at Linkou Chang Gung Memorial Hospital, and none of the subjects had developed any treatment-related side effects. CEO Dr. Arthur Lung stated that the next step would be to continue towards Proof-of-Concept phase study, and he expressed that this project would be a major proponent of NaviFUS’ product line. NaviFUS has also been conducting a safety study for another epilepsy clinical trial recently at Taipei Veterans General Hospital and has completed its first FIH case in June; the study is currently in the stage of continuing to recruit more patients. Also, continuing its previous collaboration with experts in brain tumors and epilepsy from Stanford University…
We recently had the pleasure of hosting FUS Foundation’s Chairman Neal F. Kassell and Asia Program Director Jessica Lukens, and Council Member Jessica Chao again at NaviFUS. As a focused ultrasound company in Asia, NaviFUS was visited by FUS Foundation as part of its ongoing Asia program. Chairman Jen Chen, CEO Arthur Lung, and CTO Hao-Li Liu gave them a tour of NaviFUS’ facilities and discussed with them the current state of NaviFUS’ operations, potential collaborations and opportunities with FUS Foundation, and landscape of FUS technology in Taiwan and Asia…
NaviFUS announced that their focus ultrasound system (NaviFUS system) had gotten the clinical trial approval from TFDA for the treatment of drug-resistant epilepsy(DRE). The primary goal of this trial is validation the safety of NaviFUS system using in DRE. Subjects recruiting will start in April…
